View clinical trials related to Covid19.
Filter by:The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge.
The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome. Participants will be given probiotics or placebo capsules for two month. Symptom questionnaires, cognitive function, eeg and fecal sample are recorded/collected before and after the supplement. Researchers will compare the probiotic group and the placebo to see if probiotic supplement really make differences.
The goal of this Phase 3 study is to compare the effectiveness, safety, and side effects of the CIC vaccine with approved flu vaccines and the Novavax COVID-19 Vaccine with adjuvant.
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of GS-441524 in healthy subjects. The main questions to answer are: 1) What dosage of GS-441524 is required for adequate therapeutic plasma levels? 2) Does fed or fasted state produce variability in plasma levels? 3) How is GS-441524 eliminated from the body. Participants will receive varying levels of GS-441524 or placebo to evaluate AEs and plasma levels.
The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action. The main questions it aims to answer are: - What is the clinical relevance of improvements of symptoms and quality of life after treatment with HBOT for post-COVID? - What are the changes in absence from work after treatment with HBOT? - What is the cost-effectiveness of treatment with HBOT? - What are possible mechanisms of action of HBOT? Participants will undergo 40 sessions of HBOT. Researchers will compare HBOT with standard care alone (control group). In case of a positive outcome, patients in the control group can cross-over to the HBOT group after 6 months.
This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue. Inclusion criteria are: male, female or non-binary, age ≥18 years, diagnosis of post-COVID-19 fatigue, ≥3 months since the last infection with COVID-19, fatigue severity score (cut-off) of ≥ 16 on the Chalder Fatigue Scale (CFQ-11), consent to participation, and sufficient German language skills. Exclusion criteria are a known psychiatric or somatic condition that can explain the fatigue and current participation in a multidisciplinary rehabilitation program aimed to ameliorate the consequences of COVID-19. Patients will be randomized and allocated to either an intervention group, in which they will receive access to vimida in addition to treatment as usual (TAU; n=80), or to a control group, in which they will receive access to TAU only (n=80). The primary endpoint will be fatigue symptoms with three months post-allocation (T1) being the primary time point for assessment of effectiveness. Six months post-allocation (T2) will be used as follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, mental health-related quality of life, work/social functioning, somatic symptoms, and anxiety symptoms.
This study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience.
Occupational dermatitis is the second most common occupational disease in Europe, with a notable prevalence among healthcare workers-approximately 20% of whom are affected. However, these figures may be underestimated due to underreporting. Despite the presumed scale of the problem, there is no recent European data providing real numbers. This study seeks to address the knowledge gap regarding the impact of the COVID-19 pandemic on occupational dermatitis within the healthcare workers population. EPIDERMAPS is a retrospective cohort study that analyzes data from two specialized centers in the Paris region. The primary goal is to assess changes in the proportion of dermatology-allergology consultations among healthcare workers before and after the COVID-19 pandemic. Secondary objectives include evaluating the pandemic's effect on occupational dermatoses incidences, attributed to increased PPE and hygiene products usage. The major focus will be on work-related allergic contact dermatitis, irritant contact dermatitis, contact urticaria, acne, and rosacea. The latter objective is to identify new allergens or contributing factors. Participants include active healthcare workers aged 18 or older who sought consultations for dermatological or dermatology-allergology related motifs between March 15, 2017, and March 15, 2023. Exclusions apply for patients who have consulted for other than dermatology-allergology related motif and those opposing to participate. Data will be stored, anonymized, and analyzed using EasyMedStat. Data collection is scheduled between March and December 2024. This research aims to offer insights into COVID-19's dermatologic and allergic effects on healthcare professionals, informing future preventive measures and enhanced care strategies.
Patients aged 45 to 80 years with a clinical diagnosis of stage III and IV genital prolapse involving the anterior and/or middle compartments and candidates for surgery will be considered. These will be evaluated to observe whether there is improvement in clinical prolapse with the use of the vaginal pessary during the waiting period for surgery